Azelnidipine Demonstrates Efficacy in Lowering BP in Indian Patients with Hypertension: Study

Data were collected on changes in systolic and diastolic BP from baseline to subsequent visits (4 and 12 weeks), as well as the proportion of patients achieving target BP levels.The key findings of the study were:

• Mean reduction in systolic/diastolic BP from baseline to 12 weeks: 13.92/7.91 mm Hg (p < 0.0001)

• Mean reduction in systolic/diastolic BP in newly diagnosed HTN patients: 11.77/7.43 mm Hg (p < 0.0001)

• Mean reduction in systolic/diastolic BP in known cases of HTN: 16.50/8.48 mm Hg (p < 0.0001)

• Mean reduction in systolic/diastolic BP in diabetic patients: 15.35/8.69 mm Hg (p < 0.0001)

• Proportion of patients achieving target BP of <130/80 mm Hg: 4.99%

• Proportion of patients achieving target BP of <140/90 mm Hg: 46.26%

• Mean change in heart rate (HR) from baseline: reduction of 5.22 beats/minute

The study findings suggest that azelnidipine is effective in lowering BP and HR in Indian patients with mild to moderate hypertension. With significant reductions observed in BP and HR, azelnidipine demonstrates potential as an effective antihypertensive drug in this population. These results highlight the importance of considering azelnidipine as a treatment option for hypertension management in Indian patients.

Reference: